Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W5ZU
|
||||
| Former ID |
DIB007865
|
||||
| Drug Name |
Antova
|
||||
| Synonyms |
Ruplizumab
|
||||
| Indication | Thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10:D69.6, P61.0] | Terminated | [546796] | ||
| Company |
Biogen Idec
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | Modulator | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| NF-kappa B signaling pathway | |||||
| Cell adhesion molecules (CAMs) | |||||
| T cell receptor signaling pathway | |||||
| Intestinal immune network for IgA production | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Asthma | |||||
| Autoimmune thyroid disease | |||||
| Systemic lupus erythematosus | |||||
| Allograft rejection | |||||
| Primary immunodeficiency | |||||
| Viral myocarditis | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.